Greg and Matias interview Luis Voloch, CEO and Co-Founder of Jimini Health, an AI behavioral health company. He previously co-founded and served as CTO of Immunai, where he applied machine learning to immunology and drug discovery.

In this episode, we discuss:

• How LLMs expand the scope of machine learning from rule-based tasks to open-ended reasoning and dialogue
• Why healthcare adoption is tiered, beginning with clinician-facing AI scribes and moving toward patient-facing companies with human-in-the-loop to enhance quality of care
• Why human oversight is essential and how AI can augment complex clinical work instead of replacing it
• The competitive advantage from workflows, data, and trust via purpose built AI systems
• The path toward precision psychiatry, where continuous, language-based interactions can generate rich behavioral data to inform diagnostics, treatment, and drug discovery

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Matias interviews Rob Malenka.

In this episode, we discuss:

• Why progress in psychiatry is slow because the brain is the most complex organ and many disorders are highly heterogeneous
• The bottlenecks including weak replicability in research, academic politics, perverse incentives, and pharma’s avoidance of neuropsychiatry
• How breakthroughs require early detection, rigorous science, and bridging academia with biotech through venture philanthropy
• How success depends on mission-driven, ethical people who align science, capital, and patient impact.
• The opportunities in neuromodulation, data-driven precision medicine, and combination therapies.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank

Greg and Matias interview Brendon Boot of Skin2Neuron. Brendon is a neurologist at Harvard and Mayo Clinic with prior experience as Medical Director at Biogen overseeing their Phase 1b Alzheimer’s trials.

In this episode, we discuss:

• How skin-derived cells can be turned into neurons to repair the brain.
• Why replacing lost neurons may succeed where drugs have failed in Alzheimer’s.
• What makes autologous (self-derived) cell therapy safer and more effective.
• How testing in dogs brought stronger proof than traditional mouse models.
• Why this approach could shift Alzheimer’s treatment from slowing decline to restoring memory.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Caitlin Ner & Nico V. Rey

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank